Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - difelikefalin acetate, quantity: 55 microgram (equivalent: difelikefalin, qty 50 microgram) - injection, solution - excipient ingredients: sodium chloride; sodium acetate trihydrate; acetic acid; water for injections - korsuva is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - avacopan, quantity: 10 mg - capsule, hard - excipient ingredients: shellac; iron oxide yellow; titanium dioxide; iron oxide red; gelatin; potassium hydroxide; iron oxide black; peg-40 hydrogenated castor oil; macrogol 4000; polysorbate 80 - tavneos, in combination with a rituximab or cyclophosphamide based regimen, is indicated for the treatment of adults with anti-neutrophil cytoplasmic autoantibody (anca)-associated vasculitis (granulomatosis with polyangiitis [gpa] and microscopic polyangiitis [mpa]).

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a (h1n1) haemagglutinin 7.5ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))); influenza virus a (h3n2) haemagglutinin 7.5ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))); influenza virus b (victoria) haemagglutinin 7.5ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))); influenza virus b (yamagata) haemagglutinin 7.5ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) - suspension for injection - 30 mcg/0.25ml - active: influenza virus a (h1n1) haemagglutinin 7.5ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))) influenza virus a (h3n2) haemagglutinin 7.5ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))) influenza virus b (victoria) haemagglutinin 7.5ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))) influenza virus b (yamagata) haemagglutinin 7.5ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) excipient: calcium chloride dihydrate dibasic sodium phosphate monobasic potassium phosphate monobasic sodium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. afluria quad junior vaccine is indicated for use in children aged 6 months to 35 months inclusive. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

United States - English - NLM (National Library of Medicine)

seqirus pty ltd - influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) antigen (propiolactone inactivated) (unii: 9jwn7vdq7n) (influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:u6c4gj6wzg), influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) antigen (propiolactone inactivated) (unii: a5wli8wk8a) (influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:37h6eg2naq), influenza b vi - influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - afluria® is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes a and type b present in the vaccine. afluria is approved for use in persons 5 years of age and older. afluria is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11]) . pregnancy category b: a reproductive and developmental toxicity study has been performed in female rats at a dose approximately 265 times the human dose (on a mg/kg basis) and revealed no evidence of impaired female fertility or harm to the fetus due to afluria. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, afluria should be given to a pregnant woman only if clearly needed. in the reproductive and developmental toxicity study, the effect

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - diphtheria toxoid, adsorbed 2 [iu] (not less than 2iu/0.5ml); tetanus toxoid, adsorbed 20 [iu] (not less than 20iu/0.5ml) - suspension for injection - 2iu/20iu - active: diphtheria toxoid, adsorbed 2 [iu] (not less than 2iu/0.5ml) tetanus toxoid, adsorbed 20 [iu] (not less than 20iu/0.5ml) excipient: aluminium hydroxide sodium chloride sodium hydroxide water for injection - vaccination of children (not less than 5 years of age) and adults who have previously received at least 3 doses of a vaccine for primary immunisation against diphtheria and tetanus. adt booster is not intended for primary immunisation against diphtheria and tetanus.

Canada - English - Health Canada

seqirus pty ltd - haemagglutinin-strain a (h1n1); haemagglutinin-strain a (h3n2); haemagglutinin-strain b (victoria); haemagglutinin-strain b (yamagata) - suspension - 15mcg; 15mcg; 15mcg; 15mcg - haemagglutinin-strain a (h1n1) 15mcg; haemagglutinin-strain a (h3n2) 15mcg; haemagglutinin-strain b (victoria) 15mcg; haemagglutinin-strain b (yamagata) 15mcg - vaccines

Canada - English - Health Canada

seqirus pty ltd - haemagglutinin-strain a (h1n1); haemagglutinin-strain a (h3n2); haemagglutinin-strain b (victoria); haemagglutinin-strain b (yamagata) - suspension - 15mcg; 15mcg; 15mcg; 15mcg - haemagglutinin-strain a (h1n1) 15mcg; haemagglutinin-strain a (h3n2) 15mcg; haemagglutinin-strain b (victoria) 15mcg; haemagglutinin-strain b (yamagata) 15mcg - vaccines

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - rabies vaccine 2.5 [iu] - injection with diluent - 2.5 iu - active: rabies vaccine 2.5 [iu] excipient: disodium edetate potassium l-glutamate polygeline sodium chloride sucrose trometamol water for injection - active immunisation against rabies virus, including (a) pre-exposure immunisation, (b) post-exposure treatment following exposure to rabies virus

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd -